Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
37 hedge funds and large institutions have $22.7M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 17 reducing their positions, and 3 closing their positions.
5% less funds holding
Funds holding: 39 → 37 (-2)
14% less capital invested
Capital invested by funds: $26.4M → $22.7M (-$3.68M)
59% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 17
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$210K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$67.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$58.3K |
| 4 |
State Street
Boston,
Massachusetts
|
+$35.8K |
| 5 |
Bank of New York Mellon
New York
|
+$30.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$216K |
| 2 |
Renaissance Technologies
New York
|
-$92.2K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$49.8K |
| 4 |
BlackRock
New York
|
-$49K |
| 5 |
SG Americas Securities
New York
|
-$44K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| $31K | -$7.31K | -61 | -17% |
|
27
JP Morgan Chase
New York
| $25K | +$2.88K | +24 | +11% |
|
28
BNP Paribas Financial Markets
Paris,
France
| $17K | +$13.7K | +114 | +238% |
|
29
Bank of America
Charlotte,
North Carolina
| $14K | -$8.51K | -71 | -35% |
|
|
30
Morgan Stanley
New York
| $8K | -$216K | -1,803 | -96% |
|
31
Legal & General Group
London,
United Kingdom
| $8K | -$3.12K | -26 | -25% |
|
|
SO
32
STRS Ohio
Columbus,
Ohio
| $8K | – | – | – |
|
|
AIP
33
Ameritas Investment Partners
Lincoln,
Nebraska
| $6K | – | – | – |
|
|
MAM
34
Meeder Asset Management
Dublin,
Ohio
| $4K | – | – | – |
|
35
Citigroup
New York
| $3K | -$11.5K | -96 | -73% |
|
36
Bank of Montreal
Toronto,
Ontario, Canada
| $3K | -$2.88K | -24 | -43% |
|
37
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | -$120 | -1 | -5% |
|
|
RE
38
RBC Europe
London,
United Kingdom
| $39 | – | – | – |
|
|
39
SG Americas Securities
New York
| – | -$44K | -363 | Closed |
|
40
Squarepoint
New York
| – | -$41K | -342 | Closed |
|
41
UBS Group
Zurich,
Switzerland
| – | -$23K | -190 | Closed |
|
ELOX Hedge Fund Activity: Q3 2020 in Review
37 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q3 2020, worth a combined $22.7M — down 14% from $26.4M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ELOX and 1 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 7 added.
The largest buyer was Russell Investments Group, opening a new position worth an estimated $210K. The largest seller was Morgan Stanley, cutting an estimated $216K.
- 37 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q3 2020, down from 39 in Q2 2020.
- Funds reported $22.7M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q3 2020, down 14% quarter-over-quarter.
- 1 fund opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q3 2020 and 3 closed out, a net change of -2 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q3 2020 was Russell Investments Group, an estimated $210K added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q3 2020 was Morgan Stanley, an estimated $216K sold.
Based on aggregated 13F filings for Q3 2020.